Biointron

10/16/2026

𝗔 𝗺𝗼𝗱𝘂𝗹𝗮𝗿 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗳𝗼𝗿 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗱𝗿𝘂𝗴 𝗰𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀

A recent review describes how ADC efficacy depends on several factors, including intracellular trafficking, linker cleavage, payload susceptibility, and the tumor microenvironment.

The authors propose a modular biomarker framework that considers:
• Target biology: Antigen abundance and accessibility
• ADC processing: Internalization and linker cleavage
• Payload susceptibility: Sensitivity and resistance mechanisms
• Toxicity: Biomarkers to guide dosing and improve safety

Thinking about more comprehensive, prospectively validated biomarkers could improve patient selection, therapeutic sequencing, and treatment optimization.

Find the paper here: https://www.nature.com/articles/s41571-026-01213-3

Antibody–drug conjugates (ADCs) have transformed the management of various advanced-stage solid cancers. Nonetheless, and despite considerable development efforts, many of these agents lack reliable biomarkers of clinical benefit and/or are reliant on traditional methods of biomarker assessment, w...

10/15/2026

🎉 𝗦𝗵𝗼𝘂𝘁𝗼𝘂𝘁 𝘁𝗼 𝗼𝘂𝗿 𝗤𝟯 𝟮𝟬𝟮𝟲 𝗧𝗿𝗮𝘃𝗲𝗹 𝗚𝗿𝗮𝗻𝘁 𝗪𝗶𝗻𝗻𝗲𝗿 𝗙𝗲𝗱𝗲𝗿𝗶𝗰𝗼 𝗨𝗴𝗴𝗲𝗿𝗶!

We were thrilled to see Federico Uggeri, PhD student at Università degli Studi di Milano, present at the 17th World ADC San Diego on the: “Design of Pyrrolidine-Carbamate Self-Immolative Spacers and their Application in Antibody-Drug Conjugates”.

At Biointron, we’re proud to support researchers advancing the future of antibody discovery and cancer treatment, and his work on designing next-generation antibody conjugates across multiple scales is a great example of the innovation we aim to support through our travel grant program.

👉 Interested in attending a conference with support from Biointron? Apply for our travel grant program here:

Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.

10/15/2026

📣 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝗨𝗽𝗱𝗮𝘁𝗲! 𝗕𝗶𝗼𝗶𝗻𝘁𝗿𝗼𝗻'𝘀 𝗤𝟯 𝟮𝟬𝟮𝟲 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗧𝗿𝗲𝗻𝗱𝘀 𝗶𝘀 𝗼𝘂𝘁 𝗻𝗼𝘄!

Dive into the latest trends, breakthroughs, and insights shaping the antibody industry. Gain exclusive insights into:

• 📣 10 novel antibody drugs approved for the first time in Q3 2026
• 💸 Top 20 antibody drug deals, including M&As, licensing agreements, and collaborations of up to US$2.9B
• 🤖 Artificial intelligence (AI)-driven drug discovery is moving toward experimental validation
• 🔬 mRNA-encoded antibodies allow the body's cellular machinery to transiently produce and secrete antibodies
• 💊 A list of antibody drugs with soon-approaching approval action dates to keep an eye out for in Q4 2026

Click the link to access the full report 👉

Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September.

10/12/2026

𝐓𝐡𝐞 𝟐𝟎𝟐𝟔 𝐅𝐞𝐬𝐭𝐢𝐯𝐚𝐥 𝐨𝐟 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐄𝐮𝐫𝐨𝐩𝐞 𝐢𝐬 𝐡𝐚𝐩𝐩𝐞𝐧𝐢𝐧𝐠 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰!

Our team is excited to see you at Messe Basel again! Join us at booth #308 to talk about our latest offering - RushData for your AI antibody discovery!

📅 Date: October 13 - 15, 2026
📍 Location: Messe Basel | Basel, Switzerland
🔬 Booth #308

Register for a 1-on-1 time with us here:
🔗https://www.surveymonkey.com/r/9YWFGHN

10/11/2026

𝐓𝐡𝐞 𝟐𝟎𝟐𝟔 𝐖𝐨𝐫𝐥𝐝 𝐀𝐃𝐂 𝐒𝐮𝐦𝐦𝐢𝐭 𝐢𝐬 𝐡𝐚𝐩𝐩𝐞𝐧𝐢𝐧𝐠 𝐢𝐧 𝐒𝐚𝐧 𝐃𝐢𝐞𝐠𝐨 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰!

Can't wait to see you at booth #112!

📅 Date: October 12 - 15, 2026
📍 Location: Town & Country Resort | San Diego, CA
🔬 Booth #112

Register for a 1-on-1 time with us here:
🔗https://www.surveymonkey.com/r/WYLNL39

10/07/2026

𝗪𝗵𝗮𝘁 𝗮𝗿𝗲 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗼𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗰𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲𝘀 (𝗔𝗢𝗖𝘀)?

A recent review describes how AOCs offer a novel strategy for extrahepatic delivery. Unlike antibody-drug conjugates (ADCs), AOCs have nucleic acid payloads, enabling specific gene modulation with reduced off-target effects.

While AOC candidates for conditions such as Duchenne muscular dystrophy (DMD) have progressed to Phase III trials, their development remains constrained by limited targets like TfR1, and their activity is highly dependent on antibody selection, linker design, and modification strategies.

Find the paper in Nature 👉 https://www.nature.com/articles/s41434-026-00621-5

Antibody-oligonucleotide conjugates (AOCs) effectively integrate the delivery capability of antibodies with the specific gene regulatory function of oligonucleotides, offering a novel strategy for extrahepatic delivery. Unlike antibody-drug conjugates (ADCs), AOCs employ nucleic acid payloads, enabl...

10/07/2026

🎉 𝗢𝘂𝗿 𝗤𝟯 𝟮𝟬𝟮𝟲 𝗧𝗿𝗮𝘃𝗲𝗹 𝗚𝗿𝗮𝗻𝘁 𝗪𝗶𝗻𝗻𝗲𝗿 𝗶𝘀 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝗪𝗼𝗿𝗹𝗱 𝗔𝗗𝗖 𝗻𝗲𝘅𝘁 𝘄𝗲𝗲𝗸!
Federico Uggeri, a PhD student at Università degli Studi di Milano, will be attending the 17th World ADC San Diego (October 12–15, 2026). Biointron will also be exhibiting, so be sure to meet us at Booth #112!

Federico Uggeri graduated in Chemistry cm laude at Università degli Studi di Milano in 2024, with a Master's thesis in the synthesis of salicylaldehyde-tagged peptides. He is currently pursuing his doctoral studies in Chemistry at the same institution, under the supervision of Prof. Alberto Dal Corso, with a scholarship co-funded by Takis srl (Rome, IT). His research focuses on the design and synthesis of antibody–drug conjugates (ADCs), with particular interest in the development of novel self-immolative spacers for controlled payload release. His work aims to improve the selectivity and therapeutic potential of targeted cancer therapies.

👉 Interested in attending a conference with support from Biointron? Apply for our travel grant program here: https://www.biointron.com/promotions/travel-grant-program.html

Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.

10/06/2026

𝐓𝐡𝐞 𝟐𝟎𝟐𝟔 𝐅𝐞𝐬𝐭𝐢𝐯𝐚𝐥 𝐨𝐟 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐄𝐮𝐫𝐨𝐩𝐞 𝐢𝐬 𝐢𝐧 𝟏 𝐰𝐞𝐞𝐤!

Our team is excited to see you at Messe Basel again! Join us at booth #308 to talk about our latest offering - RushData for your AI antibody discovery!

📅 Date: October 13 - 15, 2026
📍 Location: Messe Basel | Basel, Switzerland
🔬 Booth #308

Register for a 1-on-1 time with us here:
🔗https://www.surveymonkey.com/r/9YWFGHN

10/05/2026

𝐓𝐡𝐞 𝟐𝟎𝟐𝟔 𝐖𝐨𝐫𝐥𝐝 𝐀𝐃𝐂 𝐒𝐮𝐦𝐦𝐢𝐭 𝐢𝐬 𝐡𝐚𝐩𝐩𝐞𝐧𝐢𝐧𝐠 𝐢𝐧 𝐒𝐚𝐧 𝐃𝐢𝐞𝐠𝐨 𝐢𝐧 𝟏 𝐰𝐞𝐞𝐤!

We can't wait to see you at booth #112! Let us talk about how we can accelerate your projects!

📅 Date: October 12 - 15, 2026
📍 Location: Town & Country Resort | San Diego, CA
🔬 Booth #112

Register for a 1-on-1 time with us here:
🔗https://www.surveymonkey.com/r/WYLNL39

09/30/2026

𝐓𝐡𝐞 𝐀𝐑𝐃𝐃 𝟐𝟎𝟐𝟔 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 𝐢𝐬 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰! 𝐀𝐫𝐞 𝐲𝐨𝐮 𝐞𝐱𝐜𝐢𝐭𝐞𝐝?

Join us for a conversation on advances in antibody research for aging therapies!

📅 Date: October 1 - 3, 2026
📍 Location: David Rubenstein Treehouse | Boston, MA
🔬 Booth #10

Register for a 1-on-1 time with us here:
🔗https://www.surveymonkey.com/r/J2NHKBB